Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BRS051
MIFTS: 68

Breast Disease

Categories: Reproductive diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Breast Disease

About this section

MalaCards integrated aliases for Breast Disease:

Name: Breast Disease 12 15 17
Breast Diseases 56 44 45 74
Abnormality of the Breast 30

Classifications:

MalaCards categories:
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:3463
MeSH 45 D001941
NCIt 51 C26709
SNOMED-CT 69 79604008
UMLS 74 C0006145
Sources

Summaries for Breast Disease

About this section
MedlinePlus : 44 Most women experience breast changes at some time. Your age, hormone levels, and medicines you take may cause lumps, bumps, and discharges (fluids that are not breast milk). If you have a breast lump, pain, discharge or skin irritation, see your health care provider. Minor and serious breast problems have similar symptoms. Although many women fear cancer, most breast problems are not cancer. Some common breast changes are Fibrocystic breast changes - lumpiness, thickening and swelling, often just before a woman's period Cysts - fluid-filled lumps Fibroadenomas - solid, round, rubbery lumps that move easily when pushed, occurring most in younger women Intraductal papillomas - growths similar to warts near the nipple Blocked milk ducts Milk production when a woman is not breastfeeding NIH: National Cancer Institute

MalaCards based summary : Breast Disease, also known as breast diseases, is related to microglandular adenosis and in situ carcinoma, and has symptoms including pruritus, exanthema and pelvic pain. An important gene associated with Breast Disease is PRLR (Prolactin Receptor), and among its related pathways/superpathways are GPCR Pathway and Circadian entrainment. The drugs Cyclophosphamide and Epirubicin have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and bone, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

Disease Ontology : 12 A thoracic disease that is located in the breast.

Wikipedia : 77 Breast diseases make up a number of conditions. The most common symptoms are a breast mass, breast pain,... more...

Sources

Related Diseases for Breast Disease

About this section

Diseases related to Breast Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 191)
# Related Disease Score Top Affiliating Genes
1 microglandular adenosis 32.9 ERBB2 PGR TP53
2 in situ carcinoma 30.3 BRCA1 ERBB2 ESR1 KRT5 PGR TP53
3 insulin-like growth factor i 30.1 EGF ESR1 IGF1 IGFBP3
4 breast reconstruction 30.0 BRCA1 BRCA2
5 cervical cancer 29.9 CYP1A1 ERBB2 IGFBP3 KRT5 TP53 VEGFA
6 breast cancer 29.9 BRCA1 BRCA2 CTSD CYP19A1 CYP1A1 CYP1B1
7 endometriosis 29.8 CYP19A1 ESR1 ESR2 PGR VEGFA
8 breast fibroadenoma 29.6 CYP19A1 ERBB2 ESR1 PGR
9 gynecomastia 29.6 CYP19A1 ESR1 PGR
10 leiomyoma 29.6 CYP19A1 ESR1 ESR2 PGR
11 mammographic density 29.4 COMT CYP19A1 CYP1A1 CYP1B1 ESR1 IGF1
12 ductal carcinoma in situ 29.4 BRCA1 BRCA2 CYP19A1 ERBB2 ESR1 KRT5
13 sporadic breast cancer 29.3 BRCA1 BRCA2 ERBB2 ESR1 ESR2 PGR
14 mastitis 11.7
15 diabetic mastopathy 11.2
16 multiple fibroadenomas of the breast 10.9
17 breast abscess 10.8
18 hypertrophy of breast 10.8
19 fat necrosis of breast 10.8
20 infant gynecomastia 10.8
21 breast angiomatosis 10.8
22 postmenopausal atrophic vaginitis 10.6 ESR1 ESR2 PRLR
23 endometrial clear cell adenocarcinoma 10.6 CTSD ESR1
24 slipped capital femoral epiphysis 10.6 IGF1 IGFBP3
25 breast squamous cell carcinoma 10.6 ERBB2 KRT5 TP53
26 hidradenocarcinoma 10.6 ERBB2 ESR1 KRT5 TP53
27 colonic disease 10.6 CTSD ESR1 TP53 VEGFA
28 adenocarcinoma 10.6 EGF ERBB2 TP53 VEGFA
29 tonsil cancer 10.6 ERBB2 KRT5 TP53
30 gastric papillary adenocarcinoma 10.6 ERBB2 TP53
31 galactorrhea 10.6 IGF1 PRLR
32 gastrointestinal adenoma 10.6 CYP1B1 TFF1
33 colorectal adenoma 10.6 IGF1 IGFBP3 TP53
34 male reproductive system disease 10.6 ESR2 IGF1 IGFBP3 TP53 VEGFA
35 adult hepatocellular carcinoma 10.6 EGF TP53
36 stomach disease 10.6 ERBB2 TFF1 TP53 VEGFA
37 secondary adrenal insufficiency 10.6 IGF1 IGFBP3
38 respiratory system cancer 10.6 CYP1A1 ERBB2 TP53 VEGFA
39 breast cystic hypersecretory carcinoma 10.6 ERBB2 KRT5
40 exudative vitreoretinopathy 1 10.6 IGF1 IGFBP3 VEGFA
41 oral cavity cancer 10.5 CYP1A1 ERBB2 TP53 VEGFA
42 male reproductive organ cancer 10.5 ESR2 IGF1 IGFBP3 TP53 VEGFA
43 malignant spiradenoma 10.5 KRT5 TP53
44 glioblastoma multiforme 10.5 EGF ERBB2 IGF1 TP53 VEGFA
45 breast adenocarcinoma 10.5 CTSD CYP1A1 EGF ERBB2 ESR1 TP53
46 squamous cell carcinoma 10.5 CYP1A1 EGF ERBB2 TP53 VEGFA
47 sebaceous adenoma 10.5 EGF ESR1
48 comedo carcinoma 10.5 ERBB2 ESR1
49 glassy cell carcinoma of the cervix 10.5 ERBB2 ESR1 PGR
50 endometrium carcinoma in situ 10.5 PGR TP53

Graphical network of the top 20 diseases related to Breast Disease:



Diseases related to Breast Disease
Sources

Symptoms & Phenotypes for Breast Disease

About this section

UMLS symptoms related to Breast Disease:


pruritus, exanthema, pelvic pain, mastodynia, breast engorgement, nipple discharge, signs and symptoms in breast, other signs and symptoms in breast, breast pain female

MGI Mouse Phenotypes related to Breast Disease:

47 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.47 BRCA1 BRCA2 COMT CTSD CYP19A1 CYP1A1
2 homeostasis/metabolism MP:0005376 10.47 BRCA1 BRCA2 COMT CTSD CYP19A1 CYP1A1
3 growth/size/body region MP:0005378 10.46 BRCA1 BRCA2 CTSD CYP19A1 CYP1A1 EGF
4 behavior/neurological MP:0005386 10.45 BRCA1 BRCA2 COMT CTSD CYP19A1 ERBB2
5 cellular MP:0005384 10.4 BRCA1 BRCA2 CTSD CYP19A1 ERBB2 ESR1
6 integument MP:0010771 10.39 BRCA1 BRCA2 CTSD CYP19A1 EGF ERBB2
7 immune system MP:0005387 10.37 BRCA1 BRCA2 COMT CTSD CYP19A1 CYP1A1
8 digestive/alimentary MP:0005381 10.36 BRCA1 BRCA2 CTSD CYP19A1 EGF ERBB2
9 cardiovascular system MP:0005385 10.34 BRCA1 COMT CYP19A1 CYP1A1 ERBB2 ESR1
10 hematopoietic system MP:0005397 10.33 BRCA1 BRCA2 COMT CTSD CYP19A1 CYP1A1
11 limbs/digits/tail MP:0005371 10.27 BRCA1 BRCA2 ERBB2 ESR1 ESR2 IGF1
12 neoplasm MP:0002006 10.25 BRCA1 BRCA2 CYP1B1 ERBB2 ESR1 ESR2
13 embryo MP:0005380 10.23 BRCA1 BRCA2 COMT ERBB2 ESR1 PGR
14 adipose tissue MP:0005375 10.21 BRCA1 CYP19A1 ESR1 ESR2 IGF1 IGFBP3
15 nervous system MP:0003631 10.18 BRCA1 BRCA2 COMT CTSD CYP19A1 ERBB2
16 muscle MP:0005369 10.16 BRCA1 CYP19A1 ERBB2 ESR1 ESR2 IGF1
17 normal MP:0002873 10.1 BRCA1 BRCA2 CYP19A1 CYP1A1 EGF ERBB2
18 liver/biliary system MP:0005370 10.02 CYP19A1 CYP1A1 ESR1 ESR2 IGFBP3 TP53
19 reproductive system MP:0005389 9.97 BRCA1 BRCA2 COMT CYP19A1 EGF ERBB2
20 no phenotypic analysis MP:0003012 9.91 CYP1A1 ESR1 ESR2 KRT5 PGR TP53
21 renal/urinary system MP:0005367 9.86 BRCA1 COMT CYP19A1 ESR1 ESR2 IGF1
22 respiratory system MP:0005388 9.56 BRCA1 COMT ERBB2 ESR1 ESR2 IGF1
23 skeleton MP:0005390 9.4 BRCA1 BRCA2 CYP19A1 ERBB2 ESR1 ESR2
Sources

Drugs & Therapeutics for Breast Disease

About this section

Drugs for Breast Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1083)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
2
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 56420-45-2 41867
3
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-21-8 3385
4
Acetylcholine Approved, Investigational Phase 4,Phase 3,Phase 2 51-84-3 187
5
Methylene blue Approved, Investigational Phase 4,Phase 2,Not Applicable 61-73-4
6
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
7
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Early Phase 1 7439-89-6, 15438-31-0 23925 27284
8
Povidone Approved Phase 4,Phase 2 9003-39-8
9
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 64-17-5 702
10
Povidone-iodine Approved Phase 4,Phase 3 25655-41-8
11
Iodine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7553-56-2 807
12
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 55-56-1 2713 9552079
13
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33069-62-4 36314
14
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 41575-94-4 38904 10339178 498142
15
Toremifene Approved, Investigational Phase 4,Phase 3,Phase 2 89778-26-7 3005573
16
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 120511-73-1 2187
17
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 112809-51-5 3902
18
Zoledronic Acid Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 118072-93-8 68740
19
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 439-14-5 3016
20
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
21
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
22
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2 302-25-0
23
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2 2921-57-5
24
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
25
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 10540-29-1 2733526
26
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 159351-69-6 6442177 70789204
27
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
28
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53123-88-9 46835353 6436030 5284616
29
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 107868-30-4 60198
30
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 216974-75-3
31
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154361-50-9 60953
32
Sargramostim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 123774-72-1, 83869-56-1
33
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 114977-28-5 148124
34
Pertuzumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 380610-27-5, 145040-37-5 2540
35
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 180288-69-1 9903
36
Ropivacaine Approved Phase 4,Phase 3,Early Phase 1,Not Applicable 84057-95-4 71273 175805
37
Nitrous oxide Approved, Vet_approved Phase 4,Phase 3 10024-97-2 948
38
Fulvestrant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129453-61-8 104741 17756771
39
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
40
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
41
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 28523-86-6 5206
42
Vinorelbine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 71486-22-1 60780 44424639
43
Ondansetron Approved Phase 4,Phase 3,Phase 2,Not Applicable 99614-02-5 4595
44
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 2180-92-9, 38396-39-3 2474
45
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 137-58-6 3676
46
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 2078-54-8 4943
47
Phenobarbital Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-06-6 4763
48
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-23-7 5754
49
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-03-3
50
Palbociclib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 571190-30-2 11431660 5005498 5330286

Interventional clinical trials:

(show top 50) (show all 7077)
# Name Status NCT ID Phase Drugs
1 A Clinical Study on the Efficacy and Safety of the Treatment of Hyperplasia of Mammary Glands With Xiaoru Sanjie Capsule Unknown status NCT02929420 Phase 4 Xiaoru Sanjie capsules;Xiao Yao pills
2 Neoadjuvant ECS Versus ECF in Local Advanced Breast Cancer Unknown status NCT01849380 Phase 4 S-1;5-FU
3 The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction Unknown status NCT01427400 Phase 4 Botulinum Toxin-A;Saline
4 Methylene Blue Intradermal Injection for Sentinel Lymph Node Biopsy for Breast Cancer Patients Unknown status NCT02982148 Phase 4
5 The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy Unknown status NCT02905916 Phase 4 PEG-rhG-CSF
6 Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer Unknown status NCT02903524 Phase 4 Doxorubicin Hydrochloride Liposome injection and cyclophosphamide;pirarubicin and cyclophosphamide
7 Selective Lymph Node Dissection Using Fluorescent Dye in Node-positive Breast Cancer Unknown status NCT02781259 Phase 4 Indocyanine green
8 Integrated Positron Emission Tomography Magnetic Resonance (PET/MR) of Breast Cancer Unknown status NCT02766530 Phase 4
9 Sienna+® Injection Time Study 4 Arms Unknown status NCT02612870 Phase 4
10 Wound Infections in Breast Cancer Surgery After Preoperative Skin Preparation With Chlorhexidine vs. Povidone-iodine Unknown status NCT02479347 Phase 4 Chlorhexidine;Povidone-Iodine
11 Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer Unknown status NCT02207361 Phase 4 Paclitaxel, Carboplatin;Paclitaxel, Epirubicin
12 Weekly and Every 3 Week Administration of Paclitaxel Liposome Injection in Metastatic Breast Cancer Unknown status NCT02142790 Phase 4 paclitaxel liposome injection
13 Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer Unknown status NCT02089854 Phase 4 Toremifene; Anastrozole
14 Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis Unknown status NCT01956409 Phase 4 18F-FCH;Magnevist
15 Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace) Unknown status NCT01908556 Phase 4 Letrozole
16 Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer Unknown status NCT01597999 Phase 4
17 Clinical Trial Comparing Outcomes of Breast Conserving Operations With Classic v High-frequency Electrocoagulation Unknown status NCT01216254 Phase 4
18 Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene Unknown status NCT01072318 Phase 4 Letrozole
19 Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients Unknown status NCT00912938 Phase 4 zoledronic acid
20 A Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients With Taxane-Pretreated Recurrent Breast Cancer Unknown status NCT00912639 Phase 4 Paclitaxel loaded Polymeric micelle
21 Yunzhi as Dietary Supplement in Breast Cancer Unknown status NCT00647075 Phase 4
22 A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging Unknown status NCT00531973 Phase 4 liposomal doxorubicin;epirubicin
23 Study the Role of Positron Emission Mammography in Pre-surgical Planning for Breast Cancer Unknown status NCT00484614 Phase 4
24 The MONET - Study: MR Mammography of Nonpalpable Breast Tumors Unknown status NCT00302120 Phase 4
25 STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing Pilot) Unknown status NCT00126360 Phase 4 Timing of Anastrozole in respect to radiotherapy
26 Omega-3 Fatty Acids and Chemotherapy-induced Neuropathy and Inflammation in Breast Cancer Unknown status NCT01049295 Phase 4
27 Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma Unknown status NCT00307606 Phase 4 Solu-medrol 125 mg
28 Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer Unknown status NCT00030758 Phase 4
29 Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer Completed NCT00999921 Phase 4 Tamoxifen;Evening Primrose Oil
30 Single-shot Pectoral Plane(PECs) Block Versus Continuous Local Anaesthetic Infusion Analgesia or Both PECS Block and Local Anaesthetic Infusion After Breast Surgery: A Prospective Randomised, Double-blind Trial Completed NCT03024697 Phase 4
31 An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis Completed NCT01743560 Phase 4 RAD001;Exemestane
32 Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab Completed NCT02248571 Phase 4 Bevacizumab;Capecitabine;Everolimus;Exemestane
33 The Efficacy and Safety of PEG-rhG-CSF（Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive Chemotherapy Completed NCT02944604 Phase 4 PEG-rhG-CSF
34 PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy Completed NCT02805153 Phase 4 PEG-rhG-CSF;rhG-CSF
35 Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC) Completed NCT02688803 Phase 4 Dose dense AC-P;Dose dense AC;FEC-D
36 Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide Completed NCT02502864 Phase 4 Standard of Care: Docetaxel;Standard of Care: Cyclophosphamide
37 Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer Completed NCT02445586 Phase 4 Docetaxel;Pertuzumab;Trastuzumab
38 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer Completed NCT02287675 Phase 4 Lymphoseek;Sulfur Colloid
39 Sentinel Lymph Node Mapping Post-Injection Site Pain Completed NCT02065232 Phase 4 Tilmanocept;Sulfur Colloid
40 Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer Completed NCT01961544 Phase 4 Eribulin mesylate
41 Influence of Exceptional Patient Characteristics on Everolimus Exposure Completed NCT01948960 Phase 4 everolimus dose escalation
42 The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer Completed NCT01907880 Phase 4 Pamidronate;Zoledronic acid;placebo
43 Will Preoperative MRI Breast in Women Under 56 Years With Breast Cancer Change Primary Treatment Completed NCT01859936 Phase 4
44 An Open-label, Multi-center Phase â…£ Trial to Evaluate the Efficacy and Safety of Sequential Neoadjuvant Chemotherapy With Docetaxel(Monotaxel®) After Doxorubicin Plus Cyclophosphamide Combination Chemotherapy in Locally Advanced Breast Cancer Completed NCT01660542 Phase 4 Neoadjuvant Chemotherapy with Docetaxel
45 Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer Completed NCT01612871 Phase 4 Tamoxifen, Letrozole , Anastrozole, Exemestane
46 Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not Completed NCT01553903 Phase 4 Tamoxifen,;Exemestane;Anastrozole;Letrozole
47 Life Quality and Mental State in Patients With Breast Cancer Completed NCT01458457 Phase 4
48 Wound Infiltration and Breast Cancer Surgery Completed NCT01404377 Phase 4
49 A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment Completed NCT01301729 Phase 4 Docetaxel;Paclitaxel;Trastuzumab
50 Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer Completed NCT01231659 Phase 4 Everolimus + Letrozole

Search NIH Clinical Center for Breast Disease

Cochrane evidence based reviews: breast diseases

Sources

Genetic Tests for Breast Disease

About this section

Genetic tests related to Breast Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Breast 30
Sources

Anatomical Context for Breast Disease

About this section

MalaCards organs/tissues related to Breast Disease:

42
Breast, Lymph Node, Bone, Brain, Testes, Lung, Prostate

The Foundational Model of Anatomy Ontology organs/tissues related to Breast Disease:

20
The Breast
Sources

Publications for Breast Disease

About this section

Articles related to Breast Disease:

(show top 50) (show all 1312)
# Title Authors Year
1
Benign Breast Disease Increases Breast Cancer Risk Independent of Underlying Familial Risk Profile: Findings from a Prospective Family Study Cohort (ProF-SC). ( 30725480 )
2019
2
A Community-Based Assessment of Knowledge and Practice of Breast Self-Examination and Prevalence of Breast Disease in Southwest Cameroon. ( 30713554 )
2019
3
Pathology Evaluation of Reduction Mammaplasty Specimens and Subsequent Diagnosis of Malignant Breast Disease: A Claims-Based Analysis. ( 30719555 )
2019
4
The clinical role of contrast enhanced ultrasound in differential diagnosis of BI-RADS 4 breast disease. ( 30856103 )
2019
5
Clinical and histologic characteristics of breast cancers in women with previous pathologic diagnosis of benign breast disease in Spain. ( 29517151 )
2018
6
Macrophagic "Crown-like Structures" Are Associated with an Increased Risk of Breast Cancer in Benign Breast Disease. ( 29167285 )
2018
7
Select Choices in Benign Breast Disease: An Initiative of the American Society of Breast Surgeons for the American Board of Internal Medicine Choosing Wisely<sup>Ar</sup> Campaign. ( 29968026 )
2018
8
Infectious and Inflammatory Breast Disease. ( 29298955 )
2018
9
Clinicopathological Analysis of Ultrasound-guided Vacuum-assisted Breast Biopsy for the Diagnosis and Treatment of Breast Disease. ( 29599377 )
2018
10
Modern Approaches to the Surgical Management of Malignant Breast Disease: The Role of Breast Conservation, Complete Mastectomy, Skin- and Nipple-Sparing Mastectomy. ( 29080650 )
2018
11
Efficiency of Imaging Modalities in Male Breast Disease: Can Ultrasound Give Additional Information for Assessment of Gynecomastia Evolution? ( 29322116 )
2018
12
A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease. ( 29453232 )
2018
13
Subtypes of Benign Breast Disease as a Risk Factor for Breast Cancer: A Systematic Review and Meta-Analysis Protocol. ( 29398746 )
2018
14
Ultrasonographic and Mammographic Findings of Male Breast Disease. ( 29708282 )
2018
15
Evaluation of 2 breast cancer risk models in a benign breast disease cohort. ( 29932456 )
2018
16
Correction to: Association between lifestyle, menstrual/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease. ( 29644560 )
2018
17
The Effects of <i>Berberis Vulgaris</i> Juice on Insulin Indices in Women with Benign Breast Disease: A Randomized Controlled Clinical Trial. ( 29796035 )
2018
18
Ethical Considerations of Medical Photography in the Management of Breast Disease. ( 29978370 )
2018
19
Somatic mutations in benign breast disease tissue and risk of subsequent invasive breast cancer. ( 29872146 )
2018
20
A panel containing PD-1, IL-2Rα, IL-10, and CA15-3 as a biomarker to discriminate breast cancer from benign breast disease. ( 29983594 )
2018
21
Subtypes of Benign Breast Disease as a Risk Factor of Breast Cancer: A Systematic Review and Meta Analyses. ( 30046203 )
2018
22
Preferring fried dishes increases risk of benign breast disease, but not breast cancer. ( 30079899 )
2018
23
Breast fibroadenomas are not associated with increased breast cancer risk in an African American contemporary cohort of women with benign breast disease. ( 30092846 )
2018
24
Male Breast Disease: What the Radiologist Needs to Know. ( 30122313 )
2018
25
Psychosocial stress is associated with benign breast disease in young Chinese women: results from Project ELEFANT. ( 30255453 )
2018
26
Gene expression profiling of the early pathogenesis of wooden breast disease in commercial broiler chickens using RNA-sequencing. ( 30517117 )
2018
27
Recurrent Mondor's breast disease - hormonal contraceptive involvement. ( 30530952 )
2018
28
Ultrasonographic assessment of male breast diseases. ( 29316031 )
2018
29
Demonstration of an algorithm to overcome health system-related barriers to timely diagnosis of breast diseases in rural Zambia. ( 29746541 )
2018
30
MicroRNA expression in pre-treatment plasma of patients with benign breast diseases and breast cancer. ( 29849944 )
2018
31
Association of serum interleukin-10, interleukin-17A and transforming growth factor-α levels with human benign and malignant breast diseases. ( 29904427 )
2018
32
Understanding and Practices of Gynaecologists Related to Breast Cancer Screening, Detection, Treatment and Common Breast Diseases: A Study from India. ( 30051242 )
2018
33
Correction: MicroRNA expression in pre-treatment plasma of patients with benign breast diseases and breast cancer. ( 30174799 )
2018
34
Value of Ultrasound in the Detection of Benign and Malignant Breast Diseases: A Diagnostic Accuracy Study. ( 30210716 )
2018
35
Benign Breast Diseases: An Introduction for the Advanced Practice Nurse. ( 30239503 )
2018
36
Relational autonomy in breast diseases care: a qualitative study of contextual and social conditions of patients' capacity for decision-making. ( 30359251 )
2018
37
Breast diseases histologically diagnosed at a tertiary facility in Uganda (2005-2014). ( 30577784 )
2018
38
Benign Breast Diseases. ( 30800033 )
2018
39
Refining Risk Assessment in Women With Benign Breast Disease: An Ongoing Dilemma. ( 28376199 )
2017
40
Down-regulation of hK7 in the sera of breast cancer and benign breast disease patients. ( 28761938 )
2017
41
Association between lifestyle, menstrual/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease. ( 28643020 )
2017
42
Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy. ( 27933411 )
2017
43
Benign breast disease and risk of thyroid cancer. ( 28681104 )
2017
44
Cowden Syndrome: Serendipitous Diagnosis in Patients with Significant Breast Disease. Case Series and Literature Review. ( 27886412 )
2017
45
Diabetic Mastopathy: A Systematic Review of Surgical Management of a Rare Breast Disease. ( 28272124 )
2017
46
Sexual function, anxiety and depression in women with benign breast disease. A case-control study. ( 29267489 )
2017
47
Personal history of proliferative breast disease with atypia and risk of multifocal breast cancer. ( 29266172 )
2017
48
Cancer antigen 15-3, platelet distribution width, and fibrinogen in combination to distinguish breast cancer from benign breast disease in non-conclusive mammography patients. ( 28978076 )
2017
49
Breast disease in men in metropolitan SALo Paulo - Brazil. ( 28741872 )
2017
50
Association between mammographic breast density and histologic features of benign breast disease. ( 29258587 )
2017
Sources

Variations for Breast Disease

About this section
Sources

Expression for Breast Disease

About this section
Search GEO for disease gene expression data for Breast Disease.
Sources

Pathways for Breast Disease

About this section

Pathways related to Breast Disease according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
GPCR Pathway 65
Show member pathways
 13.69 BRCA1 BRCA2 EGF ERBB2 ESR1 ESR2
2
Circadian entrainment 38
Show member pathways
 12.99 COMT CTSD ESR1 ESR2 PGR TFF1
3
PI3K-Akt signaling pathway 38
Show member pathways
 12.94 BRCA1 EGF ERBB2 IGF1 PRLR TP53
4
Endometrial cancer 38
Show member pathways
 12.83 BRCA2 EGF ERBB2 IGF1 TP53 VEGFA
5
MAPK signaling pathway 1 38
12.72 EGF ERBB2 IGF1 TP53 VEGFA
6
Chks in Checkpoint Regulation 65
Show member pathways
 12.65 BRCA1 BRCA2 ESR1 ESR2 IGF1 TP53
7
Pathways in cancer 38
12.58 BRCA2 EGF ERBB2 ESR1 ESR2 IGF1
8
ErbB signaling pathway 1 38
Show member pathways
 12.54 EGF ERBB2 TP53 VEGFA
9
MicroRNAs in cancer 38
12.48 BRCA1 CYP1B1 ERBB2 TP53 VEGFA
10
Prolactin Signaling Pathway 1 38
Show member pathways
 12.45 CTSD ERBB2 ESR1 ESR2 PRLR
11
DNA Damage Response 1
Show member pathways
 12.34 BRCA1 IGF1 IGFBP3 TP53
12
Proteoglycans in cancer 38
12.25 ERBB2 ESR1 IGF1 TP53 VEGFA
13
Glioma 38
Show member pathways
 12.2 BRCA1 BRCA2 EGF ERBB2 ESR1 ESR2
14
Development Ligand-independent activation of ESR1 and ESR2 23
Show member pathways
 12.17 EGF ERBB2 ESR1 ESR2 IGF1 TFF1
15
Glioblastoma Multiforme 65
11.94 EGF IGF1 RHOC TP53
16
Gastric cancer 38
Show member pathways
 11.94 BRCA1 BRCA2 EGF ERBB2 ESR1 ESR2
17
Signaling by ERBB4 67
Show member pathways
 11.89 EGF ERBB2 ESR1 PGR PRLR
18
HIF-1 signaling pathway 38
11.88 EGF ERBB2 IGF1 VEGFA
19
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors 67
Show member pathways
 11.82 ERBB2 ESR1 VEGFA
20
Integrated Breast Cancer Pathway 1
11.82 BRCA1 BRCA2 CYP19A1 ESR1 TP53 VEGFA
21
Nuclear Receptor transcription pathway 67
Show member pathways
 11.81 ESR1 ESR2 PGR
22
BRCA1 Pathway 65
Show member pathways
 11.77 BRCA1 BRCA2 TP53
23
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 66
11.74 EGF IGF1 VEGFA
24
Platinum drug resistance 38
11.7 BRCA1 ERBB2 TP53
25
Bladder cancer 38 1
11.7 EGF ERBB2 TP53 VEGFA
26
Transcription Ligand-dependent activation of the ESR1/SP pathway 23
Show member pathways
 11.68 ESR1 PRLR VEGFA
27
Pathways Affected in Adenoid Cystic Carcinoma 1
11.65 BRCA1 ERBB2 TP53
28
Steroid hormone biosynthesis 38
Show member pathways
 11.64 COMT CYP19A1 CYP1A1 CYP1B1
29
Androstenedione and testosterone biosynthesis and metabolism p.1 23
Show member pathways
 11.56 COMT CYP19A1 CYP1A1
30
Hepatitis C and Hepatocellular Carcinoma 1
11.53 BRCA1 TP53 VEGFA
31
Differentiation Pathway 1
11.49 EGF IGF1 VEGFA
32
Ovarian steroidogenesis 38
11.49 CYP19A1 CYP1A1 CYP1B1 IGF1
33
FOXA1 transcription factor network 1
Show member pathways
 11.47 BRCA1 ESR1 TFF1
34
Aryl Hydrocarbon Receptor 1
11.46 CYP1A1 CYP1B1 ESR1 VEGFA
35
LKB1 signaling events 1
11.43 CTSD ESR1 TP53
36
Photodynamic therapy-induced HIF-1 survival signaling 1
11.36 IGFBP3 TP53 VEGFA
37
Estrogen metabolism 1
Show member pathways
 11.27 COMT CYP19A1 CYP1A1 CYP1B1
38
Ovarian Infertility Genes 1
11.21 CYP19A1 ESR2 PGR PRLR
39
Estrogen Receptor Pathway 1
10.8 CYP1A1 CYP1B1 ESR1
40
Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics 62
10.1 CYP19A1 ESR1 ESR2
Sources

GO Terms for Breast Disease

About this section

Cellular components related to Breast Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet alpha granule lumen GO:0031093 9.33 EGF IGF1 VEGFA
2 insulin-like growth factor ternary complex GO:0042567 8.96 IGF1 IGFBP3
3 insulin-like growth factor binding protein complex GO:0016942 8.62 IGF1 IGFBP3

Biological processes related to Breast Disease according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 regulation of apoptotic process GO:0042981 9.9 BRCA1 ESR1 IGFBP3 TP53
2 negative regulation of gene expression GO:0010629 9.87 ESR1 IGF1 PGR VEGFA
3 positive regulation of cell migration GO:0030335 9.85 EGF IGF1 RHOC VEGFA
4 cell proliferation GO:0008283 9.83 BRCA2 CYP1A1 ERBB2 IGF1 TP53
5 positive regulation of gene expression GO:0010628 9.73 BRCA1 EGF ERBB2 IGF1 TP53 VEGFA
6 response to estrogen GO:0043627 9.69 BRCA1 COMT ESR1
7 positive regulation of epithelial cell proliferation GO:0050679 9.67 ERBB2 IGF1 VEGFA
8 positive regulation of MAP kinase activity GO:0043406 9.65 EGF ERBB2 VEGFA
9 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.62 EGF IGF1 TP53 VEGFA
10 activation of transmembrane receptor protein tyrosine kinase activity GO:0007171 9.59 EGF PRLR
11 estrogen metabolic process GO:0008210 9.58 COMT CYP1B1
12 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.58 IGF1 IGFBP3
13 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.56 ESR1 TP53
14 omega-hydroxylase P450 pathway GO:0097267 9.54 CYP1A1 CYP1B1
15 toxin metabolic process GO:0009404 9.52 CYP1A1 CYP1B1
16 positive regulation of transcription, DNA-templated GO:0045893 9.5 BRCA1 BRCA2 EGF ESR1 ESR2 IGF1
17 negative regulation of ERBB signaling pathway GO:1901185 9.46 EGF ERBB2
18 chordate embryonic development GO:0043009 9.4 BRCA1 BRCA2
19 mammary gland development